Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Video Interview: Corbus Sees 2016 As Pivotal Year

This article was originally published in Scrip

Executive Summary

With key clinical data readouts expected at the end of 2016 and the start of 2017, Corbus Pharmaceuticals Holdings Inc.'s CEO Dr. Yuval Cohen expects the next 12 months to be pivotal for the rare inflammatory disease company. Speaking to Informa Pharma Insights global director of content Mike Ward, Cohen reveals that the company expects to report Phase II data for Resunab, its synthetic endocannabinoid-mimetic compound that binds to the CB2 receptor, in both cystic fibrosis and systemic sclerosis. Phase II data for Resunab in dermatomyositis will be available 1Q 2017.

You may also be interested in...



ACR 2016 Roundup: Remicade Copy Not So Similar; Mixed Sirukumab Results; Corbus’s Resunab Surge

At ACR: Janssen reported data that show Celltrion’s Remicade biosimilar is not quite the same, but positive sirukumab results may not boost the Janssen and GSK biologic’s market prospects. Meanwhile, Corbus surged on mid-stage resunab results in systemic sclerosis, Janssen shared Phase II gesulkumab psoriasis results, Genentech eyes a new Actemra indication, and Xencor rose on interim Phase II data.

Case Studies: How Three Public Companies Financed R&D In A Tough Market

The market for public offerings by biopharma companies is tough, but Corbus Pharmaceuticals, Loxo Oncology and Novavax used three different strategies to raise cash from new and existing shareholders.

AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments

Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.

Topics

UsernamePublicRestriction

Register

SC064406

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel